Ted Myles Appointed CEO of Cellarity

May 12, 2025
Ted Myles has been appointed as the new Chief Executive Officer of Cellarity, a life sciences company, and will also serve as CEO-Partner at Flagship Pioneering, according to a press release.

Cellarity, a life sciences company, has announced the appointment of Ted Myles as its new Chief Executive Officer. Myles will also join Flagship Pioneering as a CEO-Partner, announced in a press release.

Myles brings extensive experience in the biopharma industry, having previously served as Chief Financial Officer and Chief Operating Officer at Scholar Rock. During his tenure, he led the company through significant growth phases, including a successful Phase 3 study and raising over $1 billion in capital. His past roles also include leadership positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.

Cellarity is advancing its AI/ML-enabled platform to uncover novel druggable biology for complex diseases. The company's lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease, expected to enter clinical development in mid-2025. Myles' leadership is anticipated to be pivotal as Cellarity approaches its first clinical study this year.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.